Life Sciences Archive » June, 2024

Life Sciences - June, 2024

259 articles

• Chevron's End Is Just The Start For Energized Agency Foes
• Will 'Moral Victory' In Purdue Ruling Help Plaintiffs?
• CUNY Medical Prof Accused Of Fabricating NIH Grant Apps
• In Chevron Case, Justices Trade One Unknown For Another
• Health Regulators Likely To Tread Carefully Post-Chevron
• Shkreli Asks High Court To Toss $64M Disgorgement Order
• Rite Aid Ch. 11 Plan OK'd With Insurers' Objections Resolved
• Philips Gets OK For $25M Med Monitoring Deal In CPAP MDL
• Nationwide Cert. Rejected In Suit Over Stolen Curaleaf Tips
• Judge Finalizes $4M Deal In Eye Doc Ransomware Dispute
• 4 Things To Know As New SPAC Rules Take Effect
• Nixed Purdue Ch. 11 Plan May Leave States Ready For A Fight
• How Cannabis Rescheduling May Affect Current Operators
• Skiing And Surfing Make Me A Better Lawyer
• Supreme Court Strikes Down Chevron Deference
• 4 Firms Guide Pair Of IPOs Totaling $457M
• Biden, Trump Spar On Abortion Access In The Wake Of Dobbs
• OptumRx Agrees To Pay $20M To Resolve DOJ Opioid Claims
• State AGs Want Stay Lifted In Generic Drug Pricing Suit
• Judge Blasts Prisons Bureau, Sends Exec To Halfway House
• Insurers Call Rite Aid Ch. 11 Opioid Deal Unfair
• Rape Kit Co. Wants Wash. Ban Lifted During Free Speech Suit
• Fed. Circ. Backs Ax Of United Therapeutics' Drug Patent
• Titanic Purdue Ruling Shifts The Balance Of Power In Ch. 11
• EU High Court Upends Servier Decrease Of Pay-For-Delay Fine
• Ex-Exec Fights Sotera's Bid To Toss Del. Stock Vesting Suit
• Judge OKs $10M Deal In Generic Price-Fixing MDL
• AbbVie Buys Bowel Disease Biotech Celsius For $250M
• Calif. Justices Say Patient's Choice A Factor In Product Cases
• Class Actions At The Circuit Courts: June Lessons
• Tracking Implementation Of IRA Programs As Election Nears
• Poor Governance Tanked Genomic Co.'s Stock, Investor Says
• Unpacking The Circuit Split Over A Federal Atty Fee Rule
• Honeywell Says Sourcing Co. Backpedaled On Supply Deal
• Del. Bankruptcy Ruling Will Give D&O Insureds Nightmares
• Justices Nix 3rd-Party Liability Releases In Purdue Ch. 11 Plan
• Ex-Outcome CEO Gets 7½ Years For Fraud Conviction
• Biotech Co. Allowed To Appeal Red Cross Antitrust Immunity
• Conn. Zantac Ruling To Include Sanofi As Settlement Looms
• Justices Leave Blurry Line In Place On Misinformation Fight
• Moms For America Sues Biden Admin Over Vax Liability Law
• Design Patent Attys Wary Of Applicant Disclosure Proposal
• Justices Chide 5th Circ. In Biden Social Media Case
• Ga. High Court Told To Skip Inventor's 'Clerical Mistake' Fight
• State Data Privacy Law Patchwork: Midyear Report
• Choctaw Nation Wants 9th Circ. Rehearing In CVS Arb. Dispute
• Apple Watch Improvement Is 'Inferior,' Docs Tell 9th Circ.
• House GOP Gears Up For The End Of Chevron Deference
• Squire Patton Adds Epstein Becker Healthcare Atty In DC
• Pharma Co. PhaseBio Can Exit Ch. 11 With Wind-Down Plan
• No Matter The Purdue Ruling, Mass Tort Reform Is Needed
• High Court 'Inadvertently' Posts Order Punting Abortion Case
• High Court Axes Challenge To Biden Admin's Social Media Work
• Riley Safer Expands IP Practice With Chicago Partner
• PTAB Wipes Out UMass Skin Disease Treatment Patent
• Fed. Circ. Restores Amarin's Skinny Label Suit Against Hikma
• Sarissa Capital, Founder Settle Bioverativ Suit In Del. For $40M
• Indiana U Settles Ricin-Carrying Fruit Fly Export Violations
• Plaintiffs Firms Appealing $2.1B Fee Order In Opioid Case
• Chancery OKs $71M Premier Deal, $14M Four-Firm Fee
• UK Billionaire's Pilot Avoids Prison For Insider Trading
• Lye Buyers Can't Get Court OK For $38.5M Antitrust Deals
• After A Brief Hiccup, The 'Rocket Docket' Soars Back To No. 1
• Litigation Pro Rejoins GRSM50 In Calif. From DeHay & Elliston
• Judge Mulls BioXcel's Duty To Tell Investors Of FDA Troubles
• Alleged Contract Killing Sparks Delaware Chancery Lawsuit
• NYC Pharmacy Owners Get Jail Time For $18M Med Fraud
• Justices Undo Terror Victims' Win, Citing Twitter Decision
• LA Schools Says Pseudoscience Infected 9th Circ. Vax Ruling
• Protecting Trade Secrets In US, EU Gov't Agency Submissions
• Ark. AG Sues Pharmacy Benefit Managers Over Opioids
• Suit Over Medical Screws Filed Too Late, Texas Panel Finds
• Jurisdictional Discovery Ordered In NJ COVID Test Fraud Suit
• Catching Up With Delaware's Chancery Court
• Justices Pass On Conn. School Vaccine Mandate Fight
• Cooley-Led Therapy Developer Alumis Aims For $300M IPO
• Altria Subsidiary Allowed To Sell Menthol-Flavored Vapes
• Recruitment Trends In Emerging Law Firm Frontiers
• Biotech Co. Hits Ch. 11 With Plans For Sale And 'Reboot'
• Justices Pass On Rutgers COVID-19 Vax Mandate Case
• Drug Cos., IP Attys Back Cellect In High Court Efforts
• Drugmakers Decline To Drop Patent Listings After FTC Letters
• After Fed. Circ. Win, Bausch Sues Alvogen Over Drug Patents
• Pay-For-Delay Drug Case Not Time-Barred, UK Tribunal Says
• Ex-CEO Found Liable For $1 Now Seeks Atty Fees For Del. Suit
• Costco Sued Over PFAS In Kirkland Brand Baby Wipes
• 8 Firms To Lead 4 IPOs Totaling $806M As Action Heats Up
• 4 Tips For Drafting Earnouts To Avoid Disputes
• Taxation With Representation: Travers Smith, Potamitis Vekris
• Glassblowing Makes Me A Better Lawyer
• Ex-DEA Heads Echo GOP AGs' Call For Pot Rescheduling Hearing
• Patent Owners, Challengers Spar Over PTAB Rule Proposal
• Eli Lilly Launches Round Of Diabetes Drug Suits
• Spinal Implant Maker Can Liquidate Under Ch. 11 Plan
• 11th Circ. Upholds $2.5M Pelvic Mesh Verdict, Rules Suit Timely
• No Access To Ethics Docs For Ex-NJ Official Yet, Judge Rules
• No Atty, No Case: Judge Tosses Attack On Psychedelics Ban
• HHS Drug Pricing Program Flouts Constitution, Boehringer Says
• 11th Circ. Nixes J&J Sunscreen Benzene MDL Settlement
• Theravance, Mylan Say Chinese Co. Copied COPD Drug
• USPTO's AI-Assisted Inventions Guidance Irks ABA IP Section
• 11th Circ. Backs Stryker's Defeat Of Fired Worker's Leave Suit
• Flawed Fintiv Rule Should Be Deemed Overreach In Tech Suit
• How Associates Can Build A Professional Image
• High Court Petition Asks Justices: What's A 'Willful' Kickback?
• Company, States Battle In Court Over At-Home Rape Kits
• CORRECTED: Drug Cos., PBMs Score Win In Calif. AG's Insulin Price Suit
• Fla. Immune To Contract Suit Over COVID Tests, 4th Circ. Says
• 11th Circ. Orders New Shrimp Secrets Trial Over Judge's Exit
• High Court's Abortion Pill Ruling Shuts Out Future Challenges
• COVID Test Maker Can't Shake All Of $30M Faulty Kit Suit
• J&J Fights Law Firm's Bid To Nix Subpoenas In Talc Brawl
• Emerging Trends In ESG-Focused Securities Litigation
• Restitution Plan For Lead-Test Defects Leaves Judge Uneasy
• Orange Book Warnings Highlight FTC's Drug Price Focus
• Latham Leads Boston Scientific On $1.16B Silk Road Deal
• Firms Must Rethink How They Train New Lawyers In AI Age
• A Plaintiffs-Side Approach To Cochlear Implant Cases
• Cancer Test Company DermTech Hits Ch. 11, Seeking Sale
• Samsung Bioepis Denies Infringing Blood Treatment Patent
• Teva, DOJ Signal Key Kickback Case May Fizzle At 1st Circ.
• NJ Firm Defends Lien On Ex-Client's Patents After Unpaid Bills
• USC Allegedly Used 'Junk Science' On Black Kidney Patients
• Mifepristone Ruling Means End Of Texas DACA Suit, Feds Say
• DOJ Wants 15 Years For Outcome CEO's $1B Fraud
• Top Patent Eligibility Rulings In The Decade Since Alice
• Ex-Stimwave CEO Gets 6 Years For Dummy Implant Scheme
• HUD Freed From Pa. Pot Patients' Suit Over Housing Rebuff
• Drugmaker, PE Investor Sued In Del. Over 'Unfair' Deal Terms
• Zantac Suits Must Exit State Court, Conn. Judge Told
• Fed. Circ. Says Errors Led To Injunction In Trade Secrets Suit
• Catching Up With Delaware's Chancery Court
• Talc Claimants Want Documents In Fight Over J&J Unit Venue
• Think Like A Lawyer: Always Be Closing
• Justices Are Asked To Wade Into Blood Pressure Drug IP Fight
• Janssen Hit With $150M Verdict In HIV Drug False Claims Suit
• 3rd Circ. Merges 3 Challenges To Medicare Drug Price Talks
• Judge Won't Undo Save Of J&J Patent After Fed. Circ. Ruling
• Tracking China's Push To Invalidate Foreign Patents
• Pfizer Worker's Ex-Wife Can't Raid 401(k) To Collect Damages
• Australian Biotech Firm Telix Pharmaceuticals Pulls US IPO
• Biotech Clinches Latest Funding Round With $55M In Tow
• Takeaways From Nat'l Security Division's Historic Declination
• IP Forecast: Cooley Atty Faces DQ Bid Over Past Patent Work
• Justices Hand Abortion Advocates An Incomplete Win
• Cooley-Led Diagnostics Firm Tempus AI Raises $411M IPO
• Thomas Targets Group Standing In Mifepristone Ruling
• Full Fed. Circ. Rejects Rehearing Bids In Xifaxan Case
• Feds' Forfeiture Error Won't Tank Outcome Execs' Conviction
• Cannabis Cos. Make Deal Ahead Of Expected DEA Downgrade
• North Carolina Lawmakers Mull Outlawing 'Gas Station Heroin'
• Teva Wins Pause Of Order Ousting Patents From Orange Book
• CVS Dodges Discovery Audit In Generic Drug Collusion Suit
• GOP Lawmakers Want China Patent Data Amid Tech Pact Talks
• Vero Biotech Tried To 'String Along' Safety Monitor, Suit Says
• EU Makes First Ever Formal Pharma Price-Fixing Complaint
• JP Morgan Closes Debut Life Sciences Fund At Over $500M
• Playing Chess Makes Me A Better Lawyer
• Abortion Medication Case Ends 'With A Whimper' At High Court
• Tillis Told Drug Patents Are Too Complex For Easy Answers
• Lies At Heart Of Fraud Case Over COVID Test Kits, Jurors Told
• 2nd Circ. Backs Brokerage In Suit Over Biotech's Failed IPO
• Lipitor Buyers Get Final OK For $93M Deal In Antitrust Fight
• SPAC Dealmakers Expect Modest Pickup After Market Bottom
• Directors Of Defunct Med Tech SPAC Seek Toss Of Del. Suit
• Forte Biosciences Reaches $2M Deal To End Chancery Suit
• 'Natural' Toothpaste Brand Loaded With PFAS, Moms Say
• 32 AGs Urge Justices Take Up Okla. PBM Law Fight
• Litigation Inspiration: Attys Can Be Heroic Like Olympians
• Martin Shkreli Told To Defend Use Of Wu-Tang Album
• Pharmacy Co. Optio Gets Interim OK For $10M DIP Package
• Fed. Circ. Reinstates Parts Of Blood Analyzer Secrets Verdict
• 9th Circ. Judge On Theranos Appeal: 'Good Story' For Holmes
• AI No Scarier Than Nail Guns Or Microscopes, Kappos Says
• NJ Supreme Court Rejects Bid For Roundup Mass Tort
• Slow IPO Recovery Expected To Accelerate In 2025
• Updated Federal Rules Can Improve Product Liability MDLs
• 10 Firms Seek $13M Fee For Effexor Antitrust Deal
• Lean Into The 'Great Restoration' To Retain Legal Talent
• WilmerHale Lands Latham Atty To Help Lead Life Sciences
• FDA Urges 11th Circ. To Back E-Cig Ban Over High Nicotine
• 5 Teva Inhaler Patents Kicked Out Of Orange Book
• Bankrupt UpHealth Warned Of Criminal Charges In India
• DOJ, FDA Form Task Force To Crack Down On Illegal E-Cigs
• Baltimore Lands $45M Deal With Allergan In Opioid Litigation
• 9th Circ. Says Choctaw's Dispute With CVS Must Be Arbitrated
• Colo. Justices Say Toxic Tort Plaintiffs Didn't Waive Privilege
• Drugmakers Look To Nix Non-Insulin Claims From AG Suit
• Parexel Says Staffing Firm Liable For Temp's Alleged Fraud
• Juul Ends FOIA Suit Over FDA E-Cig Decisions
• How Cannabis Rescheduling May Alter Paraphernalia Imports
• What The NYSE Proposed Delisting Rule Could Mean For Cos.
• 9th Circ. To Hear Args In Psilocybin Right-To-Try Case
• Catching Up With Delaware's Chancery Court
• Ventilator Co. Vyaire Hits Ch. 11 As COVID Demand Wanes
• Pharmacy Biz Files Ch. 11 With More Than $235M In Debt
• Motley Rice Allocated Biggest Share Of $2B Opioid Fees
• Talc User With Cancer Had 2nd Exposure Path, Jury Hears
• Ozempic MDL Gets New Judge After Judge Pratter's Death
• Split 9th Circ. Revives LA Schools Vaccine Policy Row
• Chicago-Area Man Charged With $60M COVID Test Fraud
• Conn. Judge Pushes State For Proof In $11M Kickback Case
• DC Circ. Undoes Library Of Congress Win In Fair Use Fight
• SEC Fines Ex-AstraZeneca Insider $1.4M For Merger Trades
• Ranbaxy Units Overcome Lipitor Antitrust MDL
• Goodwin, Cooley Lead J&J-Backed Neurological Firm's IPO
• COVID Test Supplier Sees $1.4M Default Loss In Gopuff Suit
• Acorda Therapeutics Gets OK On $185M Ch. 11 Sale To Merz
• Fed. Circ. Panel Doubts Bid To Nix Actavis' $12M Deduction
• White Collar Boutique Sued By Ex-Client Over Representation
• USPTO Rejects Apple's Bids To Reexamine Masimo Patents
• Drugmakers Escape Cancer Drug Antitrust Claims For Now
• Pharma Co. Misled Investors On Seizure Drug Trial, Suit Says
• 8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
• $25 Million Flint Water Class Deal Gets Early OK
• Judge OKs $42M Stent IP Verdict, Discards Willfulness Finding
• FDA Warning Indicates Scrutiny Of Regenerative Health Cos.
• 2 Regulatory Approaches To Psychedelic Clinical Trials
• FDA Urges High Court To Hear 5th Circ. Flavored E-Cig Case
• Bankruptcy Judges Can Justly Resolve Mass Tort Cases
• Abbott Labs Must Face Bulk Of Glucerna False Ad Suit
• Biote Investors Sue Cooley, SPAC After Huge Merger Loss
• Law Firm Says Axe 'Draconian' J&J Subpoena In Talc Claim
• 'Brussels Effect' Of EU's AI Act Is Uncertain, Legal Pros Say
• Fishing Makes Me A Better Lawyer
• Pharma Co. Should Get Hungarian Rebate, ECJ Adviser Says
• USPTO Fee Hike Finds Ally In Google, But Others Have Gripes
• AI Co., Biotech Prep IPOs Worth $602M As Novelis Delays
• Medtronic Can't Pause FCA Claims For 1st Circ. Detour
• McDermott Lands King & Spalding White Collar Pro In Atlanta
• A Healthier Legal Industry Starts With Emotional Intelligence
• Pinsent Mason Guides Lab Services Biz On £11M Fundraise
• AstraZeneca Completes $2.4B Deal To Buy Pharma Co. Fusion
• Judiciary Panel Clears 1st MDL Rule, Eyes 'Mouthpiece' Amici
• Insulin Pens Exposed Patients To Disease, Hospital Says
• Biotech RenovaCare Can't Beat Investors' Stock Promo Suit
• Chinese Fund Asks To Nix Doc Bid In $830M Transaction Row
• FDA Advisers Rebuff Bid To Treat PTSD With MDMA
• Zantac Suits Belong In Conn. State Court, Cancer Patients Say
• Pharma Cos. Tell Justices Feds Support Remanding Terror Suit
• J&J Owes $260M To Ore. Talc Mesothelioma Patient, Jury Says
• Honeywell Manager 'Dismissive' Of Black Employee, Suit Says
• To Make Your Legal Writing Clear, Emulate A Master Chef
• Circuit Judge Writes An Opinion, AI Helps: What Now?
• Illumina Board Puts Grail Spinoff In Motion After EU OK
• Fed. Circ. Rulings Crystallize Polymorph Patent 'Obviousness'
• DC Circ. Ruling Heightens HHS Contract Pharmacy Challenges
• Research Co. Pays Record $35M Fine In Dog Abuse Case
• Ex-Biopharma Co. Prez Accused Of Defecting With Secrets
• Justices Won't Review Contempt Sanctions Against Drug Co.
• Glycine Co. Couldn't Compel Cooperation, Trade Court Told
• Drug Cos. Can Depose DC AG In Drug Price-Fixing Row
• 3 Infringement Defenses To Consider 10 Years Post-Nautilus
• Group Defends Plan For PED-Fueled Athletic Competitions
• Ex-SoftBank GC Joins Foley & Lardner As Partner In SF
• Biotech Firm, Mobile App Prepare To Enter IPO Fray
• House COVID Panel Questions Fauci Over Pandemic Origins
• Ropes & Gray Guides Becton On $4.2B Edwards Unit Buy
• Blockbuster Summer: 10 Big Issues Justices Still Must Decide